Self-report of current and prior antiretroviral drug use in comparison to the medical record among HIV-infected patients receiving primary HIV care

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 4, 2011, Pages 432-439

  Brouwer, Emily Suzanne ^a,b   Napravnik, Sonia ^a,b   Smiley, Sarah G ^b   Corbett, Amanda H ^c   Eron, Joseph J ^b  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Antiretroviral therapy; HIV infection; Patient education; Patient non adherence

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; DRUG USE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SELF REPORT; SENSITIVITY ANALYSIS;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DATA COLLECTION; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NORTH CAROLINA; SELF REPORT;

EID: 79953058854     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2096     Document Type: Article

References (35)

1. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367(9513): 817-824.
2. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369(9568): 1169-1178.
3. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370(9581): 29-38.
4. Moore RD, Keruly JC, Gebo KA, et al. An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002. J Acquir Immune Defic Syndr 2005; 39(2): 195-198.
5. Willig JH, Abroms S, Westfall AO, et al. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS 2008; 22(15): 1951-1960.
6. Chen RY, Westfall AO, Mugavero MJ, et al. Duration of highly active antiretroviral therapy regimens. Clin Infect Dis 2003; 37(5): 714-722.
7. Napravnik S, Keys JR, Quinlivan EB, et al. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients. AIDS 2007; 21(7): 825-834.
8. Cozzi-Lepri A, Phillips AN, Clotet B, et al. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. AIDS 2008; 22(16): 2187-2198.
9. Parruti G, Manzoli L, Toro PM, et al. Long-term adherence to first-line highly active antiretroviral therapy in a hospital-based cohort: predictors and impact on virologic response and relapse. AIDS Patient Care STDS 2006; 20(1): 48-56.
10. Simoni JM, Pearson CR, Pantalone DW, et al. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr 2006; 43 (Suppl. 1): S23-35.
11. Liu H, Miller LG, Hays RD, et al. Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr 2006; 41(3): 315-322.
12. Gross R, Yip B, Lo Re V III, et al. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis 2006; 194(8): 1108-1114.
13. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005; 191(3): 339-347.
14. Wolf MS, Davis TC, Arozullah A, et al. Relation between literacy and HIV treatment knowledge among patients on HAART regimens. AIDS Care 2005; 17(7): 863-873.
15. Miller LG, Liu H, Hays RD, et al. Knowledge of antiretroviral regimen dosing and adherence: a longitudinal study. Clin Infect Dis 2003; 36(4): 514-518.
16. Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 2006; 3(11): e438.
17. Wood E, Kerr T, Hogg RS, et al. Validity of self-reported antiretroviral therapy use among injection drug users. J Acquir Immune Defic Syndr 2006; 41(4): 530-531.
18. Hammer SM, Eron JJ, Jr., Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA Panel. JAMA 2008; 300(5): 555-570.
19. Boudreau DM, Daling JR, Malone KE, et al. A validation study of patient interview data and pharmacy records for antihypertensive, statin, and antidepressant medication use among older women. Am J Epidemiol 2004; 159(3): 308-317.
20. Sjahid SI, van der Linden PD, Stricker BH. Agreement between the pharmacy medication history and patient interview for cardiovascular drugs: the Rotterdam elderly study. Br J Clin Pharmacol 1998; 45(6): 591-595.
21. Rosenberg MJ, Layde PM, Ory HW, et al. Agreement between women's histories of oral contraceptive use and physician records. Int J Epidemiol 1983; 12(1): 84-87.
22. West SL, Strom BL, Freundlich B, et al. Completeness of prescription recording in outpatient medical records from a health maintenance organization. J Clin Epidemiol 1994; 47(2): 165-171.
23. Napravnik S, Eron JJ, Jr., McKaig RG, et al. Factors associated with fewer visits for HIV primary care at a tertiary care center in the Southeastern U.S. AIDS Care 2006; 18 (Suppl. 1): S45-S50.
24. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee and Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000; 12(3): 255-266.
25. Linjakumpu T, Hartikainen S, Klaukka T, et al. Use of medications and polypharmacy are increasing among the elderly. J Clin Epidemiol 2002; 55(8): 809-817.
26. Jorgensen T, Johansson S, Kennerfalk A, et al. Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann Pharmacother 2001; 35(9): 1004-1009.
27. Dailey G, Kim MS, Lian JF. Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of type 2 diabetic patients. J Int Med Res 2002; 30(1): 71-79.
28. Veehof L, Stewart R, Haaijer-Ruskamp F, et al. The development of polypharmacy. A longitudinal study. Fam Pract 2000; 17(3): 261-267.
29. Wolf MS, Davis TC, Osborn CY, et al. Literacy, self-efficacy, and HIV medication adherence. Patient Educ Couns 2007; 65(2): 253-260.
30. Kalichman SC, Ramachandran B, Catz S. Adherence to combination antiretroviral therapies in HIV patients of low health literacy. J Gen Intern Med 1999; 14(5): 267-273.
31. Wagner MM, Hogan WR. The accuracy of medication data in an outpatient electronic medical record. J Am Med Inform Assoc 1996; 3(3): 234-244.
32. Manley HJ, Drayer DK, McClaran M, et al. Drug record discrepancies in an outpatient electronic medical record: frequency, type, and potential impact on patient care at a hemodialysis center. Pharmacotherapy 2003; 23(2): 231-239.
33. Klungel OH, de Boer A, Paes AH, et al. Influence of correction for within-person variability in blood pressure on the prevalence, awareness, treatment, and control of hypertension. Am J Hypertens 2000; 13(1 Pt 1): 88-91.
34. Gama H, Correia S, Lunet N. Questionnaire design and the recall of pharmacological treatments: a systematic review. Pharmacoepidemiol Drug Saf 2009; 18(3): 175-187.
35. Halamka JD, Mandl KD, Tang PC. Early experiences with personal health records. J Am Med Inform Assoc 2008; 15(1): 1-7.